, Tracking Stock Market Picks
Enter Symbol:
Ims Health Incorporated (RX) [hlAlert]

down 44.30 %

Ims Health Incorporated (RX) downgraded to Underperform with price target $11 by Robert W. Baird

Posted on: Friday,  Jul 24, 2009  8:25 AM ET by Robert W. Baird

Robert W. Baird rated Underperform Ims Health Incorporated (NYSE: RX) on 07/24/2009, when the stock price was $11.73.
Since then, Ims Health Incorporated has gained 79.54% as of 02/25/2011's recent price of $21.06.
If you would have followed this Robert W. Baird's recommendation on RX, you would have lost 44.3% of your investment in 581 days.

IMS Health Incorporated (IMS) is a provider of market intelligence to the pharmaceutical and healthcare industries. IMS offers market intelligence products and services, including portfolio optimization capabilities; commercial effectiveness innovations; managed care and consumer health offerings, and consulting and services solutions. The Company?s information products are developed to meet the clients' needs by using data secured from a worldwide network of suppliers in more than 100 countries. During the year ended December 31, 2008, the Company acquired Robinson and James Research Pty Limited, Fourth Hurdle Consulting Limited, Health Benchmarks, Inc., RMBC Pharma Limited, and Skura Corporation, Inc.

Deep, comprehensive coverage is essential to your success. And with nearly 100 research professionals covering over 500 U.S. companies, our reputation for trusted, award-winning, in-depth analysis with a strong commitment to objective, fundamental research speaks for itself.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/24/2009 8:25 AM Sell
11.73 11.00
as of 12/31/2009
1 Week down  -4.26 %
1 Month down  -2.90 %
3 Months down  -43.19 %
1 YTD down  -104.92 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/24/2009 8:25 AM Hold
12.50 14.00
10/14/2008 8:25 AM Buy
16.29 22.00
12/21/2007 8:25 AM Hold
23.21 25.00
10/18/2007 9:25 AM Sell
23.12 24.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy